Literature DB >> 12706684

Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein.

Kai Schulze1, Eva Medina, Gursharan S Chhatwal, Carlos A Guzmán.   

Abstract

Protective immunity against Streptococcus pyogenes can be induced by intranasal vaccination with the fibronectin-binding domain (H12 fragment) of the fibronectin-binding protein I (SfbI) co-administered with the B subunit of the cholera toxin (CTB) as mucosal adjuvant. However, intranasal administration of A-B moiety bacterial toxins or their derivatives has been associated with potentially severe side effects. Since the SfbI protein exhibits adjuvant properties, we investigated whether vaccination with the H12 fragment alone is sufficient to promote long-lasting protection. The obtained results demonstrated that the humoral and cellular immune responses stimulated at both systemic and mucosal levels were almost identical when mice were vaccinated with the H12 fragment in the presence or absence of CTB. Immunized mice were protected against challenge with a lethal dose of S. pyogenes given 36 or 110 days after primary vaccination to the same extent (80% survival), regardless of CTB incorporation. These results demonstrate that vaccination with the H12 fragment stimulates long-lasting protective immunity. The adjuvant properties exhibited by the fibronectin-binding domain of the SfbI protein strength the potential of this antigen for inclusion in multi-component vaccines against S. pyogenes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706684     DOI: 10.1016/s0264-410x(02)00803-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Authors:  Andrea Fritzer; Beatrice M Senn; Duc Bui Minh; Markus Hanner; Dieter Gelbmann; Birgit Noiges; Tamás Henics; Kai Schulze; Carlos A Guzman; John Goodacre; Alexander von Gabain; Eszter Nagy; Andreas L Meinke
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

2.  Genetic diversity of cell-invasive erythromycin-resistant and -susceptible group A streptococci determined by analysis of the RD2 region of the prtF1 gene.

Authors:  Cinzia Spinaci; Gloria Magi; Claudia Zampaloni; Luca A Vitali; Claudia Paoletti; Maria R Catania; Manuela Prenna; Luigi Ferrante; Sandro Ripa; Pietro E Varaldo; Bruna Facinelli
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Mucosal adjuvanticity of fibronectin-binding peptide (FBP) fused with Echinococcus multilocularis tetraspanin 3: systemic and local antibody responses.

Authors:  Zhisheng Dang; Jinchao Feng; Kinpei Yagi; Chihiro Sugimoto; Wei Li; Yuzaburo Oku
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

4.  Non-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imaging.

Authors:  Faraz M Alam; Colin Bateman; Claire E Turner; Siouxsie Wiles; Shiranee Sriskandan
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.